Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp(Universitätsklinikum Würzburg), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Robin Foà(Sapienza University of Rome), Anthony S. Stein(University of Hohenheim), Svenja Neumann(Schmerzklinik Kiel), Tapan Maniar(Amgen (United States)), Gerhard Zugmaier(Amgen (Germany)), Ralf C. Bargou(Max Delbrück Center), Gary J. Schiller(Fred Hutch Cancer Center), Stephen J. Forman(City Of Hope National Medical Center), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Leonard T. Heffner(Emory University), Nicola Gökbuget(Goethe University Frankfurt), Dirk Nagorsen(Amgen (United States)), Monika Brüggemann(University Hospital Schleswig-Holstein), Adele K. Fielding(New York Blood Center), Josep‐María Ribera(Universitat Autònoma de Barcelona), Mark R. Litzow(Mayo Clinic in Arizona), Chris Holland(Amgen (United States)), Heinz A. Horst(Christian-Albrechts-Universität zu Kiel), Birgit Huber(Amgen (Germany)), Hervé Dombret(Université Paris Cité), Catherine Jia(Amgen (United States)), Susan O’Brien(University of California, Irvine)
Cited by 1,257